Theorem Clinical Research

Asia

Eisai to establish new parenteral facility in China

Friday, April 26, 2013 12:28 PM

Eisai, a Japanese pharmaceutical company, has decided to establish a new parenteral facility on a lot retained by Eisai's Chinese subsidiary, Eisai China, at the Suzhou Industrial Park in Suzhou, China. 

More... »

Quest Diagnostics

CardioDx, Core Diagnostics India ink Corus CAD marketing agreement

Friday, April 26, 2013 12:04 PM

CardioDx, a developer of cardiovascular genomic diagnostics, has signed an agreement granting Core Diagnostics India the exclusive right to market and sell its Corus CAD diagnostic test in India.

More... »


Covance expands Singapore central lab by 50%

Monday, April 22, 2013 12:44 PM

Covance, a provider of drug development services, has completed the expansion of its central laboratory facility in Singapore to enhance the company’s current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest in Covance’s continued investment in Singapore, and an important element of the strategic investment plans for the Asia Pacific region that also includes recent growth in operations in China and Japan.

More... »

inVentiv Health forms strategic alliance with Bell Medical Solutions

Tuesday, April 16, 2013 11:58 AM

inVentiv Health, a global provider of clinical, commercial and consulting services, has formed a strategic alliance with Bell Medical Solutions, a Japanese CRO with more than 700 clinical research associates serving the growing Japanese market.

More... »

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

GSK, A*STAR's ICES to develop new medicines for emerging markets

Wednesday, April 10, 2013 09:17 AM

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.

More... »

TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013 11:45 AM

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida's proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

More... »

AG Mednet, Biovisiq team up to bring clinical trial solutions to Asian market

Wednesday, April 3, 2013 09:49 AM

Executing its mission to bring zero-delay imaging technology to clinical trials around the world, AG Mednet has signed a Master Services Agreement with Biovisiq, a Japanese imaging core laboratory (ICL), with an aim to set the new industry standard for imaging data quality, compliance and efficiency.

More... »

Edison, Dainippon Sumitomo to develop orphan mitochondrial and adult CNS disease drugs

Friday, March 29, 2013 01:09 PM

Specialty pharmaceutical company Edison Pharmaceuticals has entered into a R&D and commercialization agreement with Dainippon Sumitomo Pharma, a Japanese pharmaceutical company, for the development of EPI-743 and EPI-589 in Japan.

More... »

ShangPharma’s shareholders approve merger agreement

Monday, March 25, 2013 10:02 AM

China-based pharmaceutical and biotechnology R&D outsourcing company ShangPharma’s shareholders have voted in favor of merger agreement in which ShangPharma Merger Sub will merge with ShangPharma, with the new entity being a wholly owned subsidiary of ShangPharma Parent.

More... »

`

CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs